Baudax Bio Inc - ESG Rating & Company Profile powered by AI
This ESG rating includes seventeen United Nations Sustainable Development Goals including: 'No Poverty', 'Decent Work & Economic Growth' and 'Life on Land'. Scroll down to the end of the webpage for potential risks for Baudax Bio Inc based on industry, location and marketcap. This report of Baudax Bio Inc leverages intelligence from across the web and also from available disclosures by Baudax Bio Inc.
Baudax Bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.8; made up of an environmental score of 4.0, social score of 5.3 and governance score of 8.0.
5.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 521 | Smruthi Organics Ltd | 5.9 | High |
| 521 | Vectura Group PLC | 5.9 | High |
| 541 | Baudax Bio Inc | 5.8 | High |
| 541 | Cantargia AB | 5.8 | High |
| 541 | Amplia Therapeutics Ltd | 5.8 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Baudax Bio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Baudax Bio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Baudax Bio Inc report the average age of the workforce?
Sign up for free to unlockDoes Baudax Bio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Baudax Bio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Baudax Bio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Baudax Bio Inc offer flexible work?
Sign up for free to unlockDoes Baudax Bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Baudax Bio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Baudax Bio Inc conduct supply chain audits?
Sign up for free to unlockDoes Baudax Bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Baudax Bio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Baudax Bio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Baudax Bio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Baudax Bio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Baudax Bio Inc disclose water use targets?
Sign up for free to unlockDoes Baudax Bio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Baudax Bio Inc have a product recall in the last two years?
Sign up for free to unlockDoes Baudax Bio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Baudax Bio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Baudax Bio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Baudax Bio Inc disclose parental leave metrics?
Sign up for free to unlockDoes Baudax Bio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Baudax Bio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Baudax Bio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Baudax Bio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Baudax Bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Baudax Bio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Baudax Bio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Baudax Bio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Baudax Bio Inc disclose its waste policy?
Sign up for free to unlockDoes Baudax Bio Inc report according to TCFD requirements?
Sign up for free to unlockDoes Baudax Bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Baudax Bio Inc disclose energy use targets?
Sign up for free to unlockDoes Baudax Bio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Baudax Bio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Baudax Bio Inc
These potential risks are based on the size, segment and geographies of the company.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.